Humacyte (NASDAQ:HUMA) Stock Price Target Raised at Barclays

Key Points

• Barclays raised its Humacyte price target from $0.50 to $0.60 while maintaining an “equal weight” rating; at the reported share price of $0.61, the target implies 2.28% downside.
• Analyst opinions vary: MarketBeat reports an overall “Moderate Buy” consensus and an average $4.98 price target, based on six Buy, one Hold and one Sell rating.
• Humacyte’s latest reported quarter fell short of expectations, with a loss of $0.16 per share versus a forecast loss of $0.11 and revenue of $0.41 million versus a $1.04 million estimate.

Humacyte (NASDAQ:HUMA - Get Free Report) had its target price hoisted by investment analysts at Barclays from $0.50 to $0.60 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has an "equal weight" rating on the stock. Barclays's price target indicates a potential downside of 2.28% from the stock's current price.

HUMA has been the topic of a number of other reports. HC Wainwright restated a "buy" rating on shares of Humacyte in a research report on Friday, October 16th. Benchmark reduced their price target on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research report on Thursday, August 13th. Wall Street Zen downgraded shares of Humacyte from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Williams Trading set a $1.00 price target on shares of Humacyte in a research note on Friday, October 16th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Humacyte in a research report on Friday, October 2nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $4.98.

Humacyte Stock Performance

Shares of NASDAQ HUMA traded up $0.02 during trading hours on Wednesday, reaching $0.61. The stock had a trading volume of 1,938,955 shares, compared to its average volume of 7,553,928. The firm has a market cap of $170.57 million, a price-to-earnings ratio of -1.26 and a beta of 2.64. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07. Humacyte has a fifty-two week low of $0.34 and a fifty-two week high of $1.52. The firm has a 50-day moving average of $0.49 and a 200-day moving average of $0.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $1.04 million. Equities research analysts predict that Humacyte will post -0.40 earnings per share for the current year.

Institutional Trading of Humacyte

Several hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC acquired a new position in shares of Humacyte during the third quarter worth about $491,000. HBK Investments L P acquired a new stake in Humacyte in the second quarter valued at about $617,000. Miramontes Capital LLC purchased a new stake in Humacyte in the 2nd quarter valued at approximately $85,000. Alyeska Investment Group L.P. purchased a new stake in Humacyte in the 2nd quarter valued at approximately $4,700,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in Humacyte in the 2nd quarter valued at approximately $28,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte News Summary

Here's some of the latest news about HUMA:

• Positive Sentiment: Upcoming clinical and regulatory catalysts: Humacyte plans to submit a supplemental BLA in November for ATEV in hemodialysis access. Five presentations at the November 17–21 VEITHsymposium will feature Phase 3 dialysis-access data, long-term vessel evidence and Symvess trauma experience, potentially raising awareness among vascular specialists. VEITHsymposium announcement
• Positive Sentiment: Analyst support: BTIG reaffirmed its Buy rating and $2 price target, providing a favorable view of potential upside. BTIG rating
• Negative Sentiment: Commercial and clinical risks remain: Revenue is still small, and Symvess has a boxed warning for potentially life-threatening graft failure, along with risks including rupture, anastomotic failure and thrombosis. These factors could temper investor confidence and adoption.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company's platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.